Suven Life Sciences on Wednesday said it has been granted a product patent by Australia and Singapore corresponding to a new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases. These patents are valid through 2036, the company said in a BSE filing.
“We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally,” Suven Life Chief Executive Officer Venkat Jasti said.
The compounds are being developed as therapeutic agents useful in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, attention-deficient hyperactivity disorder, Huntington’s disease, Parkinson’s and schizophrenia, it added. Suven Life Sciences’ shares were trading 1.21 per cent up at Rs 221.70 apiece on the BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.